Simponi Aria FDA Approval History
Last updated by Judith Stewart, BPharm on Oct 5, 2020.
FDA Approved: Yes (First approved July 18, 2013)
Brand name: Simponi Aria
Generic name: golimumab
Dosage form: Injection
Company: Janssen Biotech, Inc.
Simponi Aria (golimumab) is a tumor necrosis factor (TNF) blocker indicated for the treatment of:
- Adult patients with moderately to severely active Rheumatoid Arthritis (RA) in combination with methotrexate
- Active Psoriatic Arthritis (PsA) in patients 2 years of age and older
- Adult patients with active Ankylosing Spondylitis (AS)
- Active polyarticular Juvenile Idiopathic Arthritis (pJIA) in patients 2 years of age and older
Development timeline for Simponi Aria
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
